Compare DexCom, Inc. (DXCM) vs KKR & Co Inc (KKR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs KKR & Co Inc — how do they compare? DexCom, Inc. trades at $77.32 (market cap $28.06B), while KKR & Co Inc trades at $102.4 (market cap $90.64B). The key difference: KKR & Co Inc is far larger — about 3.2× DexCom, Inc.'s market cap, and KKR & Co Inc pays a 0.74% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | KKR | |
|---|---|---|
Market Cap | $28.06B | $90.64B |
Sector | Health | Financials |
52-Week High | $89.53 | $152.16 |
52-Week Low | $54.84 | $83.88 |
Enterprise Value | $27.03B | $16.16B |
Dividend Yield | — | 0.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $77.31, up 4.3% on the day, with a bullish technical outlook as it approaches resistance near $78. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.56 surpassing expectations of $0.47. Revenue growth accelerated to $4.66 billion in 2025, while net income margin expanded to 17.93%. Recent regulatory approvals, including Health Canada authorization for the G7 15-day CGM, support continued international expansion.
The stock offers growth potential with analyst consensus price target of $84.33, though high valuation multiples (P/E 31.21) and competition in the CGM market present risks. Expansion into non-insulin Type 2 diabetes and pediatric markets could drive future revenue, but commercial uptake remains unproven. Institutional sentiment remains strongly bullish with 80% buy ratings.
KKR trades at $102.21, up 5.14% with a bullish technical outlook and strong analyst support. Recent earnings beat expectations in Q1 2026, and the firm is expanding through joint ventures in renewable energy and acquisitions like EDF Power Solutions. Cash flow improved to $1.78B in 2025, though revenue dipped to $19.21B. The stock is near its 52-week high, with RSI indicating potential overbought conditions.
Outlook is positive with a consensus price target of $122.71, but risks include volatile cash flows and high debt. Growth drivers are strategic expansions and strong institutional backing, yet investors should monitor execution on recent deals and macroeconomic impacts on asset management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About KKR & Co Inc
KKR is one of the world's largest alternative asset managers, with $490.7 billion in total assets under management, including $384.5 billion in fee-earning AUM, at the end of June 2022. The company has two core segments: asset management (which includes private markets--private equity, credit, infrastructure, energy and real estate--and public markets--primarily credit and hedge/investment fund platforms) and insurance (following the February 2021 purchase of a 61.5% economic stake in Global Atlantic Financial Group, which is engaged in retirement/annuity and life insurance lines as well as reinsurance). On the asset management side, private markets account for 50% of fee-earning AUM and 70% of base management fees, while public markets account for 50% and 30%, respectively.
Read more on KKR →
